Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 101Lung Neoplasms 41Neoplasms 13Neoplasm Metastasis 11Colorectal Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 6Pancreatic Neoplasms 5Mesothelioma, Malignant 5Mesothelioma 5Carcinoma 5Meningeal Carcinomatosis 4Melanoma 4Colonic Neoplasms 4Advanced Solid Tumors 4Rectal Neoplasms 3Ovarian Neoplasms 3Lung Diseases 3Carcinoma, Bronchogenic 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Thoracic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Non-squamous Non-small Cell Lung Cancer 2Non-Squamous Non-small Cell Lung Cancer 2Non-Small Cell Lung Cancer Metastatic 2Non Small Cell Lung Carcinoma NSCLC 2Neoplasms by Site 2

Interventions

pembrolizumab 2durvalumab 2Tretinoin 2Paclitaxel 2Oxaliplatin 2Irinotecan 2Chemoradiotherapy 2Carboplatin 2Capecitabine 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1tislelizumab 1tegafur-gimeracil-oteracil 1talazoparib 1sarilumab 1relugolix 1pexidartinib 1pertuzumab 1patritumab 1olaparib 1niraparib 1neratinib 1ganitumab 1enzalutamide 1dostarlimab 1cemiplimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × Pemetrexed × 90 days × Clear all
NCT06694454 2026-05-27

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡